Latest News
-

2025: Year in Review
⏱️34 min read | As we usher in 2026, we look back on the landmark clinical trial findings, advancements in research, regulatory disappointments, and thunderous community unity that will define 2025 for the Huntington’s disease community.
-

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-

Switch off the genome editor when you’re done
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-

A new way of thinking about trials to prevent Huntington's disease
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-

New roles for huntingtin: removing a healthy protein to understand its function
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
-

Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-

A step forward for gene editing: CRISPR-Cas9 and HD
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-

Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-

New study reveals a potential HD biomarker
A potential HD biomarker has been uncovered in a recent clinical study
-

Huntington's Disease Therapeutics Conference 2017 – Day 3
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta

